United Kingdom (UK)
Recombinant monoclonal antibody to IDH1 R132H. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 10G5-1.
UniProt Accession Number of Target Protein: O75874
Alternative Name(s) of Target: IDH; IDH1; IDPc; Isocitrate dehydrogenase [NADP] cytoplasmic; Isocitrate dehydrogenase 1; Cytosolic NADP-isocitrate dehydrogenase; NADP(+)-specific ICDH; Oxalosuccinate decarboxylase
Immunogen: The original antibody was generated by immunizing BALB/c mice with human IDH-R132H polypeptide (KPIIGHHAYGDQYC) with an N-terminal BSA conjugation.
Specificity: This antibody binds human isocitrate dehydrogenase 1 (IDH1) having R132H mutation. IDH1 is an enzyme that catalyzes the NADP+-dependent oxidative decarboxylation of isocitrate (D-threo-isocitrate) to 2-ketoglutarate (2-oxoglutarate), which is required by other enzymes such as the phytanoyl-CoA dioxygenase. It plays a critical role in the generation of NADPH, an important cofactor in many biosynthesis pathways. The NADPH produced from isocitrate dehydrogenase 1 is involved in the breakdown of fats for energy, and it also protects cells from potentially harmful molecules called reactive oxygen species. Mutation in IDH1 are found in several genetic conditions and in some types of cancer, including gliomas, cartilaginous tumors, acute myelogenous leukemia, myelodysplastic syndromes, and brain cancer.
Application Notes: The binding reactivity of this antibody to R132H mutant of human IDH1 was determined using ELISA. The original mouse IgG antibody binds IDH1 R132H mutant with an affinity of Kd= 5.76 X10 ^(-10) M. This antibody was used in the immunohistochemical analysis for detection of IDH1 R132H protein in cancerous tissues (CN108727500).
Antibody first published in: PMID: